CRVS Corvus Pharmaceuticals
- 2.290
- +0.100+4.57%
- 2.300
- +0.010+0.44%
Corvus Pharmaceuticals News
Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Adaptimmune Therapeutics (ADAP) and Corvus Pharmaceuticals (CRVS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Editas Medicine (EDIT), Corvus Pharmaceuticals (CRVS) and AC Immune SA (ACIU)
Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Arcutis Biotherapeutics (ARQT) and Corvus Pharmaceuticals (CRVS)
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating
Cantor Fitzgerald Reiterates Overweight on Corvus Pharma, Maintains $4 Price Target
Corvus Pharma Analyst Ratings
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating
Oppenheimer Initiates Coverage on Corvus Pharmaceuticals With Outperform Rating, $7 Price Target
The Latest Analyst Ratings for Corvus Pharma
Mizuho Reiterates Neutral on Corvus Pharma, Maintains $3.5 Price Target
Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Corvus Pharmaceuticals (CRVS)
Ladenburg Thalmann Maintains Buy on Corvus Pharma, Raises Price Target to $10
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $4 From $2, Maintains Overweight Rating
Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS) and Caribou Biosciences (CRBU)
Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and Corvus Pharmaceuticals (CRVS)
Ladenburg Thalmann Initiates Coverage On Corvus Pharmaceuticals With Buy Rating, Announces Price Target of $2
Analysis
Price Target
No Data
